Literature-reported formulation composition
Component: CS22021 | Reported component ratio: 49.25 | Role: Ionizable lipid
sales@dcchemicals.com
Lipid CS22021
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: DOPE | Reported component ratio: 49.25 | Role: Helper phospholipid
Literature-reported formulation composition
Component: M-DMG-PEG2K | Reported component ratio: 1.5 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported ratio sum | Reported component ratio: 100 | Role: Original ratio retained
Table 2
CS22021 / helper / M-DMG-PEG2K: DSPC: 49.25 : 49.25 : 1.5 | N/P: 8 | Size (nm): 63.41 | PDI: 0.13 | EE (%): 87 | Zeta (mV): +1.14
Table 2
CS22021 / helper / M-DMG-PEG2K: DOPE: 49.25 : 49.25 : 1.5 | N/P: 8 | Size (nm): 83.13 | PDI: 0.091 | EE (%): 89 | Zeta (mV): -4.77
Table 3
SI sample name: Luc-CS22021 | Size (nm): 83.13 | PDI: 0.091 | EE (%): 89 | Zeta (mV): -4.77
Table 3
SI sample name: Luc-ALC-0315 | Size (nm): 78.16 | PDI: 0.088 | EE (%): 93 | Zeta (mV): -7.18
Table 3
SI sample name: gE-CS22021 | Size (nm): 102.6 | PDI: 0.096 | EE (%): 97 | Zeta (mV): -7.94
Table 3
SI sample name: gE-ALC-0315 | Size (nm): 75.92 | PDI: 0.069 | EE (%): 92 | Zeta (mV): -3.46
Reported observation
Literature-reported Particle size 83.13 nm SI Table S1: CS22021/DOPE/M-DMG-PEG2K formulation SI Table S1, p. S3; Luc-CS22021 in Table S2, p. S7
Reported observation
Literature-reported Polydispersity index 0.091 SI Table S1: CS22021/DOPE/M-DMG-PEG2K formulation SI Table S1, p. S3; Table S2, p. S7
Reported observation
Literature-reported mRNA encapsulation efficiency 89% SI Table S1: CS22021/DOPE/M-DMG-PEG2K formulation SI Table S1, p. S3; Table S2, p. S7
Reported observation
Literature-reported Zeta potential -4.77 mV SI Table S1: CS22021/DOPE/M-DMG-PEG2K formulation SI Table S1, p. S3; Table S2, p. S7
Reported observation
Literature-reported Apparent LNP pKa (TNS) 5.804 Formulated nanoparticles; not neat-lipid pKa · ALC-0315-based 4C-LNP: 6.267 SI Fig. S6, p. S9
Reported observation
DOPE versus DSPC in Hep3B cells The plotted luciferase signal is higher for the DOPE formulation than the DSPC formulation. Exact numerical means and a statistical comparison are not printed. Luciferase assay; mean with SEM; qualitative reading of the figure. · SI Fig. S3, p. S5
Reported observation
Cell-line-dependent transfection CS22021 shows higher plotted luciferase signals in HeLa and A549, substantially lower signal in HEK293T, and similar signal in Hep3B relative to ALC-0315. This does not support a claim of universally superior transfection. Mean with SEM; exact means are not digitized. The caption has HEK203T, whereas the graph labels HEK293T. · SI Fig. S4, p. S6
Reported observation
IV reporter biodistribution Whole-animal imaging was performed at 6, 12 and 24 h; organs were imaged at 24 h. The plots show lower whole-animal and liver/spleen expression for CS22021 than ALC-0315 under this IV condition. This result does not establish IM injection-site localization. 5 micrograms mRNA/mouse; male BALB/c, 6-8 weeks; n=3; qualitative graph comparison. · SI Fig. S5, p. S8
Reported observation
Localized IM expression and immune responses The indexed main-article abstract reports localized mRNA expression at the IM injection site, robust humoral and cellular responses to a VZV mRNA vaccine, and significantly higher CD8+ T-cell responses versus a conventional LNP. It provides no effect size or immunization schedule. Abstract-level qualitative findings; cancer-vaccine use is proposed as a potential application, not demonstrated tumor efficacy in the available evidence. · Main-article abstract, PMID 40503610
Reported observation
Cell viability and safety evidence HEK293T CCK-8 viability is plotted near the control level under the tested conditions. Rat serum ALT/AST measurements are shown for days 18 and 24. The supplied SI lacks the full rat dosing regimen and a numerical statistical safety comparison; no clinical safety or no-toxicity claim is made. SI Fig. S7: CCK-8 at 24 h after exposure. Fig. S9 illustrates a 0-4 muscle inflammation scoring scale, not treatment-group outcome scores. · SI Fig. S7, p. S10; Fig. S8, p. S11; Fig. S9, p. S12